Detalles de la búsqueda
1.
Randomized study of danoprevir/ritonavir-based therapy for HCV genotype 1 patients with prior partial or null responses to peginterferon/ribavirin.
J Hepatol
; 62(2): 294-302, 2015 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-25239078
2.
Randomized controlled trial of danoprevir plus peginterferon alfa-2a and ribavirin in treatment-naïve patients with hepatitis C virus genotype 1 infection.
Gastroenterology
; 145(4): 790-800.e3, 2013 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-23811112
3.
Hepatic steatosis in patients with chronic hepatitis C virus genotype 2 or 3 does not affect viral response in patients treated with peginterferon alpha-2a (40KD) (PEGASYS) plus ribavirin (COPEGUS) for 16 or 24 weeks.
Liver Int
; 29(2): 237-41, 2009 Feb.
Artículo
en Inglés
| MEDLINE | ID: mdl-18710427
4.
A phase Ib study to assess the efficacy and safety of vismodegib in combination with ruxolitinib in patients with intermediate- or high-risk myelofibrosis.
J Hematol Oncol
; 11(1): 122, 2018 09 24.
Artículo
en Inglés
| MEDLINE | ID: mdl-30249277
5.
Clinical utility of a blood-based EGFR mutation test in patients receiving first-line erlotinib therapy in the ENSURE, FASTACT-2, and ASPIRATION studies.
Lung Cancer
; 126: 1-8, 2018 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-30527172
6.
Maintenance erlotinib versus erlotinib at disease progression in patients with advanced non-small-cell lung cancer who have not progressed following platinum-based chemotherapy (IUNO study).
Lung Cancer
; 102: 30-37, 2016 12.
Artículo
en Inglés
| MEDLINE | ID: mdl-27987585
Resultados
1 -
6
de 6
1
Próxima >
>>